This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC), specifically in patients with advanced stages of the disease that cannot be surgically removed. The study is investigating the effects of a combination of two medications, Durvalumab and Domvanalimab (also known by the code name AB154), compared to Durvalumab with a placebo. Durvalumab is a medication that helps the immune system fight cancer, and Domvanalimab is a type of antibody that targets specific proteins in the body to help control the cancer. The purpose of the study is to see if the combination of these two medications is more effective than using Durvalumab alone.

Participants in this study are those whose cancer has not worsened after receiving a specific type of treatment called chemoradiation therapy, which combines chemotherapy and radiation. The study will involve regular monitoring of the participants’ health and the progression of their cancer over a period of time. The treatment will be administered through an infusion, which means the medication is given directly into the bloodstream through a vein. The study aims to determine if the combination of Durvalumab and Domvanalimab can help improve the time patients live without their cancer getting worse.

Throughout the study, participants will receive either the combination of Durvalumab and Domvanalimab or Durvalumab with a placebo. The study will last for a set period, during which participants will be closely monitored by healthcare professionals. The goal is to gather information on how well the treatment works and its safety. This research could potentially lead to new treatment options for patients with advanced NSCLC, providing hope for better management of this challenging condition.